NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Alendronate 70 mg tablets
Drug: Zoledronic acid 5 mg solution
Drug: Calcium/Vitamin D

First Posted Date: 2006-11-29

Last Posted Date: 2011-07-01

Lead Sponsor: Novartis

Target Recruit Count: 604

Registration Number: NCT00404820

Locations: 🇩🇪
For site information contact Novartis Pharmaceuticals, Multiple Cities, Germany

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 150 μg
Drug: Indacaterol 300 μg
Drug: Placebo

First Posted Date: 2006-11-27

Last Posted Date: 2011-08-17

Lead Sponsor: Novartis

Target Recruit Count: 50

Registration Number: NCT00403845

Locations: 🇯🇵
Novartis Investigative site, Kasukabe, Japan
🇯🇵
Novartis Investigator Site, Tokyo, Japan
🇯🇵
Novartis Investigative Site, Wakayama, Japan

Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2006-11-27

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 45

Registration Number: NCT00403637

Locations: 🇺🇸
North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸
Colorado Allergy and Asthma Centres, P.C., Denver, Colorado, United States
🇺🇸
Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States

and more 2 locations

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Amlodipine
Drug: Hydrochlorothiazide

First Posted Date: 2006-11-22

Last Posted Date: 2011-03-10

Lead Sponsor: Novartis

Target Recruit Count: 556

Registration Number: NCT00402103

Locations: 🇩🇪
Investigative Center, Investigative Center, Germany
🇧🇪
Investigator Site, Investigative Site, Belgium
🇨🇭
Investigative Site, Investigative Site, Switzerland

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Phase 4

Completed

Conditions: Maintenance Kidney Transplant

Interventions: Drug: Mycophenolate mofetil
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)

First Posted Date: 2006-11-17

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis

Target Recruit Count: 136

Registration Number: NCT00400647

Locations: 🇨🇭
Novartis, Basel, Switzerland

Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-11-17

Last Posted Date: 2008-06-18

Lead Sponsor: Novartis

Target Recruit Count: 460

Registration Number: NCT00400777

Locations: 🇧🇷
Novartis, Rio de Janeiro, Brazil

Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study

Phase 1

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2006-11-15

Last Posted Date: 2007-05-07

Lead Sponsor: Novartis

Target Recruit Count: 12

Registration Number: NCT00399945

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Phase 3

Terminated

Conditions: Opioid-induced Constipation

First Posted Date: 2006-11-15

Last Posted Date: 2012-05-01

Lead Sponsor: Novartis

Target Recruit Count: 360

Registration Number: NCT00399659

Locations: 🇺🇸
Investigative Site, Seattle, Washington, United States

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Atenolol
Drug: Hydrochlorothiazide (HCTZ))
Drug: Valsartan

First Posted Date: 2006-11-07

Last Posted Date: 2011-06-06

Lead Sponsor: Novartis

Target Recruit Count: 30

Registration Number: NCT00396656

Locations: 🇨🇭
Novartis Pharma Ag, Basel, Switzerland

Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
COPD
Lung Diseases, Obstructive

First Posted Date: 2006-11-07

Last Posted Date: 2011-10-25

Lead Sponsor: Novartis

Target Recruit Count: 51

Registration Number: NCT00396604

Locations: 🇧🇪
Novartis, Vilvoorde, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy